April 2021 at a glance: focus on systolic function, quality of life and treatment in heart failure

2021 ◽  
Vol 23 (4) ◽  
pp. 505-506
Author(s):  
Matteo Pagnesi ◽  
Marianna Adamo ◽  
Marco Metra
Keyword(s):  
Quality Of Life ◽  
Heart Failure ◽  
Systolic Function

Quality of Life in Patients With Signs and Symptoms of Heart Failure—Does Systolic Function Matter?

2006 ◽  
Vol 12 (9) ◽  
pp. 677-683 ◽  
Author(s):  
Archana Rao ◽  
Mohsen Asadi-Lari ◽  
John Walsh ◽  
Robert Wilcox ◽  
David Gray
Keyword(s):  
Quality Of Life ◽  
Heart Failure ◽  
Systolic Function ◽  
Signs And Symptoms

scholarly journals Systolic Function as a Predictor of Mortality and Quality of Life in Long-term Survivors with Heart Failure

2008 ◽  
Vol 31 (3) ◽  
pp. 119-124 ◽  
Author(s):  
Robert L. McNamara ◽  
Bethany A. Austin ◽  
Yongfei Wang ◽  
Grace L. Smith ◽  
Viola Vaccarine ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Heart Failure ◽  
Systolic Function ◽  
Long Term Survivors

scholarly journals Sacubitril/valsartan versus candesartan in women with heart failure receiving adjuvant therapy for breast cancer - is there any antiarrhythmic effect?

2020 ◽  
Vol 27 (3) ◽  
pp. 34-41
Author(s):  
S. G. Kanorskii ◽  
V. P. Pavlovets
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Heart Failure ◽  
Troponin I ◽  
Systolic Function ◽  
Holter Monitoring ◽  
Life Questionnaire ◽  
Valsartan Group ◽  
Minute Walk

Purpose. To compare the effects of sacubitril/valsartan and candesartan on the occurrence and course of heart arrhythmias in the standard treatment of heart failure (HF) in patients with breast cancer receiving anthracycline antibiotics as part of adjuvant polychemotherapy. Methods. The study involved 127 women aged 53 to 65 who received radical surgical and subsequent treatment for breast cancer in the MAMME clinic in Krasnodar in 2017-2020. Patients were prescribed adjuvant polychemotherapy, including anthracyclines, from 6 cycles. After randomization, standard HF therapy was carried out simultaneously with chemotherapy using sacubitril/valsartan (n=63) or candersartan (n=64). Initially, after the first, third and last courses of special cancer therapy, the heart rate was assessed using standard electrocardiography, 24-hour Holter monitoring of the electrocardiogram, transthoracic echocardiography, a 6-minute walk test were performed, and the level of the N-terminal pro-B type natriuretic peptide and high-sensitivity cardiac troponin I, the Minnesota Quality of Life Questionnaire for patients with chronic HF was completed.Results. According to the 24-hour Holter monitoring of the electrocardiogram, the burden of ventricular premature contraction significantly decreased in the sacubitril/valsartan group (p=0.018), but not in candesartan group (p=0.326). The proportion of patients with persisting episodes of unstable ventricular tachycardia was also significantly reduced in patients randomized to take sacubitril/valsartan (p=0.027), but practically did not change in the candesartan group (p=0.785). Physical exercise tolerance, a 6-minute walk distance, and a quality of life indicator significantly improved only in the sacubitril/valsartan group. According to echocardiography, sacubitril/valsartan improved systolic function of the left ventricle, and candesartan only prevented its decline under the influence of the damaging effects of chemotherapy.Conclusion. The efficacy and safety of treating patients who received cardiotoxic adjuvant chemotherapy for breast cancer, a decrease in the burden of ventricular arrhythmias, noted in the sacubitril/valsartan group, were a consequence of the intensification of treatment for HF. The cardiotoxic effect of anthracyclines can be overcome thanks to the pronounced positive neurohumoral effects of modern pharmacotherapy of HF using sacubitril/valsartan, which leads to a limitation of myocardial remodeling.

scholarly journals Comparison of effectiveness of therapy with lisinopril and fosinopril in patients with diastolic chronic heart failure in the presence of hypertension disease

2019 ◽  
Vol 16 (2) ◽  
pp. 6-11
Author(s):  
Svetlana N Merzlyakova ◽  
Iosif Z Shubitidze ◽  
Vitalii G Tregubov ◽  
Vladimir M Pokrovskiy
Keyword(s):  
Quality Of Life ◽  
Heart Failure ◽  
Chronic Heart Failure ◽  
Combination Therapy ◽  
Systolic Function ◽  
Subjective Evaluation ◽  
Left Ventricular ◽  
Left Ventricular Ejection ◽  
Ventricular Ejection Fraction

Aim. Сompare the effectiveness of combination therapy with lisinopril and fosinopril in patients with diastolic chronic heart failure (CHF) in the presence of hypertension disease (HD), considering its impact on the regulatory adaptive status (RAS). Materials and methods. The study take parted 69 patients with CHF II functional class according to the classification of the New York Heart Association in the presence of HD III stage with preserved systolic function of the left ventricle (left ventricular ejection fraction ≥50%), who were randomized into two groups for treatment with lisinopril (13.7±3.7 mg/day, n=34) or fosinopril (14.5±4.1 mg/day, n=35). As part of combination pharmacotherapy, patients were included nebivolol (7.2±2.4 mg/day and 7.0±2.2 mg/day), and acetylsalicylic acid when required (100 mg/day, n=8 and 100 mg/day, n=7), atorvastatin (15.7±4.9 mg/day, n=14 and 16.9±4.6 mg/day, n=16) respectively. Initially and after six months, the following was done: a quantitative evaluation of the RAS (by cardio-respiratory synchronism test), echocardiography, holter monitoring of blood electrocardiograms, all-day monitoring of pressure, treadmill test, determination of the N-terminal precursor of the natriuretic brain peptide level in blood plasma, six-minute walking test, subjective evaluation of quality of life. Results. Both combined pharmacotherapy schemes comparably improved structural and functional state of the heart, neurohumoral activation and optimized blood pressure. However, in this case, the use of fosinopril, in comparison with lisinopril, positively affected on RAS, increased exercise tolerance and improved quality of life more. Conclusion. In patients with diastolic CHF in the presence of HD III stage as part of the combination therapy, the use of fosinopril, in comparison with lisinopril, may be preferable because of a more pronounced positive effect on RAS.

Sign in / Sign up

Export Citation Format

Share Document